EconPapers    
Economics at your fingertips  
 

Shaping a research agenda to ensure a successful European health technology assessment: insights generated during the inaugural convention of the European Access Academy

Elaine Julian, Mira Pavlovic, Oriol Sola-Morales, Fabrizio Gianfrate, Mondher Toumi, Heiner C. Bucher, Christian Dierks, Wolfgang Greiner, Peter Mol, Jean-François Bergmann, Tomas Salmonson, Ansgar Hebborn, Mathilde Grande, Antonella Cardone and Jörg Ruof ()
Additional contact information
Elaine Julian: R-Connect Ltd
Mira Pavlovic: Medicines Development and Training (MDT) Services
Oriol Sola-Morales: Fundació HiTT
Fabrizio Gianfrate: University of Ferrara
Mondher Toumi: Aix-Marseille University
Heiner C. Bucher: University Hospital Basel and University of Basel
Christian Dierks: Dierks+Company Rechtsanwaltsgesellschaft mbH
Wolfgang Greiner: Bielefeld University
Peter Mol: University of Groningen
Jean-François Bergmann: University Paris-Cité and AP-HP
Tomas Salmonson: Consilium
Ansgar Hebborn: Efpia
Mathilde Grande: AMEDICONSEIL
Antonella Cardone: Cancer Patients Europe
Jörg Ruof: R-Connect Ltd

Health Economics Review, 2022, vol. 12, issue 1, 1-15

Abstract: Abstract Objectives Key challenges for a joint European Health Technology Assessment (HTA) include consolidated approaches towards the choice of adequate comparator(s), selection of endpoints that are relevant to patients with a given disease, dealing with remaining uncertainties as well as transparent and consistent management of related processes. We aimed to further crystallize related core domains within these four areas that warrant further research and scrutiny. Methods Building on the outcomes of a previously conducted questionnaire survey, four key areas, processes, uncertainty, comparator choice and endpoint selection, were identified. At the inaugural convention of the European Access Academy dedicated working groups were established defining and prioritizing core domains for each of the four areas. The working groups consisted of ~ 10 participants each, representing all relevant stakeholder groups (patients/ clinicians/ regulators/ HTA & payers/ academia/ industry). Story books identifying the work assignments were shared in advance. Two leads and one note taker per working group facilitated the process. All rankings were conducted on an ordinal Likert Response Scale scoring from 1 (low priority) to 7 (high priority). Results Identified key domains include for processes: i) address (resource-) challenge of multiple PICOs (Patient/ Intervention/ Comparator/ Outcomes), ii) time and capacity challenges, iii) integrating all involved stakeholders, iv) conflicts and aligning between different multi-national stakeholders, v) interaction with health technology developer; for uncertainty: i) early and inclusive collaboration, ii) agreement on feasibility of RCT and acceptance of uncertainty, iii) alignment on closing evidence gaps, iv) capacity gaps; for comparator choice: i) criteria for the choice of comparator in an increasingly fragmented treatment landscape, ii) reasonable number of comparators in PICOs, iii) shape Early Advice so that comparator fulfils both regulatory and HTA needs, iv) acceptability of Indirect Treatment Comparisons (ITC), v) ensure broad stakeholder involvement in comparator selection; for endpoint selection: i) approaching new endpoints; ii) patient preferences on endpoints; iii) position of HTA and other stakeholders; iv) long-term generation and secondary use of data; v) endpoint challenges in RCTs. Conclusions The implementation of a joint European HTA assessment is a unique opportunity for a stronger European Health Union. We identified 19 domains related to the four key areas, processes, uncertainty, comparator choice and endpoint selection that urgently need to be addressed for this regulation to become a success.

Keywords: EU HTA; Uncertainty; Comparators; Endpoints; Process; Clinical Trial Design; Patient-relevance; Access (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1186/s13561-022-00402-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:12:y:2022:i:1:d:10.1186_s13561-022-00402-x

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/s13561-022-00402-x

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-20
Handle: RePEc:spr:hecrev:v:12:y:2022:i:1:d:10.1186_s13561-022-00402-x